April 09, 2021
Article
The newest research of rare adverse events among patients administered the vaccine highlights that venous or arterial thrombosis can develop in unexpected regions, including the brain or abdomen, 5-20 days after administration.
A new commentary from experts highlight the evolving understanding of antibody response in vaccinated transplant patients.
April 05, 2021
Video
An expert stresses the need to consider individuals' worry over information—and even their history with systemic biases.
Vaccine access and new cases are both increasing. An expert discusses earning trust in at-risk communities.
April 02, 2021
Health regulators in the UK have now found 30 cases involving rare blood clot events after the administration of the AstraZeneca COVID-19 vaccine, but still recommend its use.
The 2 revisions made to the EUA pertain to the number of doses allotted to the current vials containing the vaccine, and allow a new vial that has a maximum of 15 doses.
April 01, 2021
The companies are now seeking a Biologics License Application with the FDA, which would allow it to become more greatly available for adults in the US.
March 31, 2021
The pivotal phase 3 data, based off 18 reported cases among placebo patients, includes the companies' intention to request authorization for adolescents aged 12-15 years old.
March 29, 2021
Cases have increased by 16%, while 50 million have now been fully vaccinated. Federal leadership is asking Americans to hold on longer.
March 23, 2021
A statement hours after the company reported promising interim phase 3 data stated the Data Safety and Monitoring Board believes they included outdated data “which may have provided an incomplete view of the efficacy data.”
